Mitoxantrone
- Generic Name
- Mitoxantrone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2014-07-23
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 6
- Registration Number
- NCT02198482
- Locations
- 🇩🇪
Hospital Aschaffenburg, Aschaffenburg, Germany
🇩🇪Helios Hospital Bad Saarow, Bad Saarow, Germany
🇩🇪Vivantes Hospital Neukölln, Berlin, Germany
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: BlinatumomabDrug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneOther: Pharmacological StudyDrug: EtoposideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MitoxantroneDrug: Mitoxantrone HydrochlorideRadiation: Radiation TherapyDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 669
- Registration Number
- NCT02101853
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection
- Conditions
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02043756
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
- Conditions
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 50
- Registration Number
- NCT02021825
- Locations
- 🇨🇳
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 41
- Registration Number
- NCT01842672
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Levine Children's Hospital, Charlotte, North Carolina, United States
Brentuximab Vedotin + Re-induction Chemotherapy for AML
- Conditions
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01830777
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: dexamethasoneDrug: vincristine sulfateBiological: rituximabDrug: clofarabineDrug: cyclophosphamideDrug: etoposideBiological: aldesleukinDrug: pegaspargaseDrug: methotrexateDrug: mercaptopurineDrug: cytarabineDrug: mitoxantroneDrug: teniposideDrug: vinblastineBiological: natural killer cell infusionOther: laboratory biomarker analysisProcedure: allogeneic hematopoietic stem cell transplantationDrug: therapeutic hydrocortisoneDevice: CliniMACS
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01700946
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Lenalidomide Plus Chemotherapy for AML
- Conditions
- Interventions
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01681537
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 25
- Registration Number
- NCT01594918
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸UCSF Comprehensive Cancer Center, San Francisco, California, United States
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 119
- Registration Number
- NCT01522443
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.